The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1-
,5-a]pyrimidin-3-yl]methanones with at least one substituent on the
4-pyridinyl ring having the chemical structure of formula I: 1
The invention further provides compositions and methods employing the
novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone-
s of formula I in to modulate GABA and GABA receptor physiology to elicit
therapeutic responses in mammalian subjects to alleviate neurological or
psychiatric disorders, including stroke, head trauma, epilepsy, pain,
migraine, mood disorders, anxiety, post traumatic stress disorder,
obsessive compulsive disorders, mania, bipolar disorders, schizophrenia,
seizures, convulsions, tinnitus, neurodegenerative disorders including
Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's
disease, Huntington's chorea, depression, bipolar disorders, mania,
trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral
ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus,
essential tremor, dyskinesia and other movement disorders, neonatal
cerebral hemorrhage, and spasticity, as well as other psychiatric and
neurological disorders mediated by GABA and/or GABA receptors.